This site is intended for Healthcare professionals only.

Sanofi, Regeneron say late-stage Dupixent trials show positive results


Sanofi, Regeneron say late-stage Dupixent trials show positive results

PARIS: Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues.

Sanofi and Regeneron said in a joint statement that two pivotal Phase 3 placebo-controlled trials evaluating Dupixent (dupilumab), in adults with inadequately controlled chronic rhinosinusitis with nasal polyps, had met all primary and secondary endpoints.

The U.S. Food & Drug Administration regulator is expected to approve Dupixent for asthma treatment before the year-end.



Source: REUTERS
0 comment(s) on Sanofi, Regeneron say late-stage Dupixent trials show positive results

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted